Diagnostic performance of ¹⁸F‑FDG PET/CT vs. ¹⁸F‑NaF PET/CT in breast cancer with bone metastases: An indirect comparative meta‑analysis.

ABSTRACT: Breast cancer remains the leading cause of cancer-related death in women, with 5-year survival rates of as high as 90% for patients with early-stage breast cancer without metastasis, falling to 10% once bone metastases (BM) occur. Currently, there is no cure for breast cancer with BM. However, appropriate treatment can extend survival and improve patients' quality of life. Therefore, it is important to accurately evaluate the presence of BM in patients with breast cancer. The present meta-analysis evaluated the diagnostic performance of ¹⁸F-FDG and ¹⁸F-NaF as PET/CT tracers for breast cancer-associated BM. The present study aimed to compare the diagnostic performance of fluorine-18 fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomograph

SUBMITTER: Hu H 

PROVIDER: S-EPMC11420642 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature